PTC THERAPEUTICS, INC. Operating Income

Quick Answer

PTC THERAPEUTICS, INC. reported Operating Income of $866.93 million for fiscal year 2025.

PTC THERAPEUTICS, INC. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 $866.93M +386.5%
2024 -$302.57M +31.2%
2023 -$439.50M +1.8%
2022 -$447.41M -19.5%
2021 -$374.44M +13.3%
2020 -$431.77M -79.0%
2019 -$241.16M -108.5%
2018 -$115.69M -79.9%
2017 -$64.29M +51.3%
2016 -$132.06M +21.0%
2015 -$167.13M -68.1%
2014 -$99.41M -119.0%
2013 -$45.40M -69.3%
2012 -$26.81M -187.7%
2011 $30.58M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 $3.02M +105.5% +108.6%
June 30, 2025 -$34.96M +13.1% -103.6%
March 31, 2025 $970.23M +2234.6% +1879.9%
September 30, 2024 -$54.51M +53.9% -35.5%
June 30, 2024 -$40.22M +80.8% +11.5%
March 31, 2024 -$45.45M +61.4% +61.5%
September 30, 2023 -$118.16M -73.3% +43.6%
June 30, 2023 -$209.54M -126.9% -78.2%
  • PTC THERAPEUTICS, INC. showed an increase of +386.5% in Operating Income compared to the prior fiscal year.
  • Over the 2011–2025 period, PTC THERAPEUTICS, INC.’s operating income has grown by 2734.8% (from $30.58 million to $866.93 million).
  • The most recent figure is from PTC THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment